Novartis AG — Director's Dealing 2018

Apr 23, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Surface Oncology, Inc. (SURF)
CIK: 0001718108
Period of Report: 2018-04-23

Reporting Person: Novartis Institutes for BioMedical Research, Inc. (10% Owner)
Reporting Person: NOVARTIS AG (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-04-23	Common Stock	C	2272726	—	Acquired	2272726	Direct
2018-04-23	Common Stock	C	909090	—	Acquired	3181816	Direct
2018-04-23	Common Stock	P	766666	$15.00	Acquired	3948482	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-04-23	Series A Preferred Stock	$	C	1571429	Disposed		Common Stock (2272726)	Direct
2018-04-23	Series A-1 Preferred Stock	$	C	5214286	Disposed		Common Stock (909090)	Direct

Footnotes

F1: The 1,571,429 shares of Series A Preferred Stock held by the Reporting Person automatically converted upon the closing of the Issuer's initial public offering into 2,272,726 shares of the Issuer's Common Stock without payment or further consideration.

F2: The 5,214,286 shares of Series A-1 Preferred Stock held by the Reporting Person automatically converted upon the closing of the Issuer's initial public offering into 909,090 shares of the Issuer's Common Stock without payment or further consideration.

F3: The shares are held directly by Novartis Institutes for BioMedical Research, Inc. ("NIBRI"). NIBRI is an indirect wholly-owned subsidiary of, and controlled by, Novartis AG.

F4: Not applicable.